Non-Clinical Safety of GRAd Vector-Based COVID-19 and HIV Vaccines Supports a Platform Regulatory Approach
Authors:
- Reji PaalangaraReji Paalangara
- Stephanie GohinStephanie Gohin
- Alexis MenardAlexis Menard
- Charlotte AmyCharlotte Amy
- Wahiba BerrabahWahiba Berrabah
- Alexandra RogueAlexandra Rogue
- Matthew A. GetzMatthew A. Getz
- Aljawharah AlrubayyiAljawharah Alrubayyi
- Simone BattellaSimone Battella
- Angelo RaggioliAngelo Raggioli
- Michela GentileMichela Gentile
- Anthea Di RitaAnthea Di Rita
Open Access
Abstract
Background/Objectives: The rapid development of safe and efficacious vaccines is often hindered by extensive, mandated non-clinical safety evaluations in animals. With the aim to provide scientific evidence supporting a “vaccine platform approach”, here we present the complete non-clinical studies for two investigational vaccines, GRAd-COV2 and GRAdHIVNE1, based on GRAd, a gorilla-derived group C adenoviral vector. Methods: The biodistribution of GRAd genomes following the intramuscular administration of the vaccines was assessed in rats by a sensitive qPCR method. Local tolerance and systemic toxic effects were evaluated in single- and repeated-dose toxicity studies in rabbits. Results: GRAd-COV2 and GRAdHIVNE1 were well-tolerated. Distribution was highly confined to the injection site and draining lymph nodes, and toxicity profile consisted of transient, non-adverse inflammatory responses, while the expected immune responses to the encoded antigens were successfully induced. Notably, both vaccines demonstrated a consistent safety profile despite transgene and backbone differences, comparable to other replication-defective adenoviral vectors. Conclusions: The established non-clinical safety profile of the GRAd platform provides a robust foundation for a more efficient and streamlined regulatory pathway. By leveraging this prior knowledge, future GRAd-based vaccines can achieve accelerated clinical development while fully adhering to the ethical principles of replacement, reduction, and refinement of animal use in research.Keywords
All Related Versions
Funding Information
- Regione Lazio and Italian Ministry of research
- Gates Foundation (INV-059646 (ReiThera Srl))
- Gates Foundation (INV-008696)
- Gates Foundation (INV-064567 (Ragon Institute))
- Gates Foundation (INV-007375)
- Gates Foundation (INV-065025 (IAVI))
This publication has 39 references indexed in Scilit:
- Global Estimates of Lives and Life-Years Saved by COVID-19 Vaccination During 2020-2024JAMA Health Forum, 2025
- Accelerating vaccine development: Plug-and-play platforms for emerging infectious diseasesVirus Research, 2025
- Evaluation of non-clinical toxicity studies of COVID-19 vaccinesRegulatory Toxicology and Pharmacology, 2023
- GRAd-COV2 vaccine provides potent and durable humoral and cellular immunity to SARS-CoV-2 in randomized placebo-controlled phase 2 trialCell Reports Medicine, 2023
- Non-clinical immunogenicity, biodistribution and toxicology evaluation of a chimpanzee adenovirus-based COVID-19 vaccine in rat and rhesus macaqueArchives of Toxicology, 2022
- AZD1222 (ChAdOx1 nCov-19): A Single-Dose biodistribution study in miceVaccine, 2021
- Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19Molecular Therapy, 2021
- Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessmentVaccine, 2021
- Nonclinical safety assessment of repeated administration and biodistribution of ChAd3‐EBO‐Z Ebola candidate vaccineJournal of Applied Toxicology, 2020
- Viral vectors as vaccine platforms: deployment in sightCurrent Opinion in Immunology, 2011